Telomir Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company focused on developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative diseases. The company's lead investigational compound, Telomir-1 (also known as Telomir-Zn), is a novel, orally administered small molecule engineered to function as a metal-ion regulator. It modulates intracellular metal homeostasis (specifically iron, copper, and zinc) and epigenetic regulation to address upstream biological drivers of disease progression, such as oxidative stress, telomere shortening, and mitochondrial dysfunction.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead product candidate, Telomir-Zn (Telomir-1), into clinical trials following FDA IND clearance. The planned Phase 1/2 trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity in approximately 76 patients with advanced or metastatic triple-negative breast cancer.
Expected impact: Establish clinical proof-of-concept and determine the recommended Phase 2 dose.
Conducting ongoing preclinical research to evaluate Telomir-1 across multiple therapeutic areas, including Type 2 diabetes (rat models), Wilson's disease (copper regulation), and age-related conditions.
Expected impact: Identify and validate additional clinical indications for future IND applications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Consolidates global intellectual property and development rights for the Telomir-1 (Telomir-Zn) platform under Telomir Pharmaceuticals, eliminating prior geographic fragmentation between North American and international rights.
Financial impact: Secured $1.0 million in cash funding at closing, with a binding commitment for up to an additional $4.0 million in optional milestone-based contributions tied to IND acceptance and Phase 1/2 trial initiation.
Strategic Partnerships
Enables Telomir to execute and analyze preclinical studies and validate scientific findings without the overhead of massive in-house laboratory and manufacturing infrastructure.
Terms: Collaborative research agreements with terms aligned to study milestones.